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Aims To assess long-term (78 weeks) alirocumab treatment in patients with heterozygous familial hypercholesterolaemia
(HeFH) and inadequate LDL-C control on maximally tolerated lipid-lowering therapy (LLT).
Methods
and results
In two randomized, double-blind studies (ODYSSEY FH I, n ¼ 486; FH II, n ¼ 249), patients were randomized 2 : 1 to
alirocumab 75 mg or placebo every 2 weeks (Q2W). Alirocumab dose was increased at Week 12 to 150 mg Q2W if
Week 8 LDL-C was ≥1.8 mmol/L (70 mg/dL). Primary endpoint (both studies) was percentage change in calculated
LDL-C from baseline to Week 24. Mean LDL-C levels decreased from 3.7 mmol/L (144.7 mg/dL) at baseline to
1.8 mmol/L (71.3 mg/dL; 257.9% vs. placebo) at Week 24 in patients randomized to alirocumab in FH I and from
3.5 mmol/L (134.6 mg/dL) to 1.8 mmol/L (67.7 mg/dL; 251.4% vs. placebo) in FH II (P, 0.0001). These reductions
were maintained through Week 78. LDL-C ,1.8 mmol/L (regardless of cardiovascular risk) was achieved at Week
24 by 59.8 and 68.2% of alirocumab-treated patients in FH I and FH II, respectively. Adverse events resulted in discon-
tinuation in 3.4% of alirocumab-treated patients in FH I (vs. 6.1% placebo) and 3.6% (vs. 1.2%) in FH II. Rate of injection
site reactions in alirocumab-treated patients was 12.4% in FH I and 11.4% in FH II (vs. 11.0 and 7.4% with placebo).
Conclusion In patients with HeFH and inadequate LDL-C control at baseline despite maximally tolerated statin+other LLT,
alirocumab treatment resulted in significant LDL-C lowering and greater achievement of LDL-C target levels and
was well tolerated.
Clinical trial
registration
Cinicaltrials.gov (identifiers: NCT01623115; NCT01709500).
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Introduction
Heterozygous familial hypercholesterolaemia (HeFH) is the most
common autosomal dominant genetic disorder, with an estimated
prevalence of 1 : 200 to 1 : 500 in the general population.1 Patients
with HeFH are characterized by elevated levels of LDL-C. Exposure
to high LDL-C levels from birth in HeFH is associated with a mark-
edly increased risk for cardiovascular (CV) events. Before the ad-
vent of statin use, the risk of CV events was reported to be
100-fold greater in patients with HeFH (aged 20–39 years) than
the general population.2 The risk of CV events was still greatly ele-
vated 8 years later, despite widespread use of statins.3 In two obser-
vational studies,4,5 80% of adult patients with HeFH did not
achieve an LDL-C level of ,2.5 mmol/L (100 mg/dL) despite
treatment with maximum doses of statins (and addition of ezetimibe
in many cases). An LDL-C level of ,1.8 mmol/L (70 mg/dL) is
recommended for patients with HeFH who are at very high CV
risk (i.e. established coronary heart disease [CHD], diabetes, or
for previously untreated individuals .40 years old).1
Inhibition of proprotein convertase subtilisin/kexin type 9
(PCSK9) represents a potential means of reducing LDL-C levels.6
Previously, alirocumab was assessed in a small (n ¼ 77) dose-ranging
study in patients with HeFH.7 The current report describes results
of two Phase 3 studies that evaluated the efficacy and safety of the
fully human monoclonal PCSK9 antibody alirocumab over 78 weeks
in patients with HeFH.
Methods
ODYSSEY FH I and FH II were randomized, double-blind, placebo-
controlled Phase 3 studies with similar designs.8 FH I was performed
at 89 sites across North America, Europe, and South Africa; FH II was
performed across 26 sites in Europe. Study protocols were approved
by the relevant institutional review boards or independent ethics com-
mittees. All patients provided written informed consent.
Patients
Patients with HeFH who did not have a history of CV events, and those
who had suffered a myocardial infarction (MI) or ischaemic stroke, were
both eligible for participation if their LDL-C levels were not at goal ac-
cording to current guidelines9 for primary [≥2.6 mmol/L (100 mg/dL)]
or secondary [≥1.8 mmol/L (70 mg/dL)] prevention, respectively.
HeFH diagnosis was either by genotyping or clinical criteria (Simon
Broome criteria or World Health Organization/Dutch Lipid Network
criteria with a score of.8 points). All patients were receiving stable high-
dose statin therapy (rosuvastatin 20–40 mg, atorvastatin 40–80 mg, or
simvastatin 80 mg; lower doses were allowed with an investigator-
documented justification, e.g. intolerance to higher statin doses), with
or without other lipid-lowering therapy (LLT), for at least 4 weeks prior
to screening (6 weeks for fenofibrate; fibrates other than fenofibrate
were not allowed). Patients with known homozygous FH or fasting serum
triglyceride levels .4.5 mmol/L (400 mg/dL) were excluded. Further
exclusion criteria are given in the Supplementary material online.
Study procedures
Patients were randomized in a 2 : 1 fashion to receive either alirocumab
75 mg every 2 weeks (Q2W) or placebo. Randomization was stratified
by history of MI or ischaemic stroke, statin treatment (atorvastatin
40–80 mg or rosuvastatin 20–40 mg daily vs. simvastatin whatever
the daily dose, atorvastatin ,40 mg daily, or rosuvastatin ,20 mg daily),
and geographic region (FH I only). The dose of alirocumab was increased
in a blinded fashion to 150 mg Q2W at Week 12 if the patient’s LDL-C
level at Week 8 was ≥1.8 mmol/L (70 mg/dL). Alirocumab 75
and 150 mg doses and placebo were each administered as a single
1 mL subcutaneous injection using a prefilled pen. Each patient (or their
caregiver) was trained to administer injections at home. Throughout the
study, patients continued with their stable statin dose and other LLT and
were instructed to follow a stable National Cholesterol Education Pro-
gram Adult Treatment Panel III Therapeutic Lifestyle Changes diet or
equivalent.
At the end of the 78 week treatment period in each study, patients
were given the option to enter a 3 year open-label extension study (cur-
rently ongoing) in which all patients are administered alirocumab. If pa-
tients decided not to enter the open-label treatment period, they were
followed up for 8 weeks post-treatment.
All lipid measurements and laboratory tests were performed using
standard procedures by a central laboratory (see Supplementary mater-
ial online).
Endpoints
The primary endpoint for both studies was the per cent change in cal-
culated LDL-C from baseline to Week 24. This was analysed using an
intention-to-treat (ITT) approach, including values obtained after stop-
ping treatment in patients who discontinued therapy. Secondary end-
points are listed in the Supplementary material online and include the
per cent change in LDL-C levels in an on-treatment analysis (using
measurements that were collected while patients were still receiving
treatment) as well as the proportion of patients reaching calculated
LDL-C ,2.6 mmol/L (for those without prior CV events) and
,1.8 mmol/L (for those with prior CV events) at Week 24; the propor-
tion of patients reaching LDL-C ,1.8 mmol/L regardless of prior CV
events was also calculated.
Safety was assessed through adverse events reports, laboratory data,
electrocardiogram, and vital signs. Treatment-emergent adverse events
(TEAEs) were defined as any adverse event that developed, worsened,
or became serious during the period from first to last injection plus 70
days (or to the first injection in the open-label extension, whichever
came first). CV events and deaths were adjudicated by an independent
Clinical Events Committee.
Development of anti-drug antibodies (ADAs) to alirocumab was as-
sessed in all patients. Samples were collected at clinic visits prior to
study-drug administration, at Weeks 0, 12, 24, 52, and 78, and at follow-
up visit and were assessed using a validated assay by Regeneron Pharma-
ceuticals, Inc. (Tarrytown, NY, USA). The cut-points for the ADA assay
were generated using baseline samples from the patient population and
incorporated false-positive rates recommended by both industry
Whitepapers and agency guidelines (see references in Supplementary
material online).
Statistical analysis
A total sample size of 45 patients (30 in the alirocumab and 15 in the
placebo group) was calculated to provide 95% power to detect a differ-
ence in mean per cent change in LDL-C of 30% with a 0.05 two-sided
significance level, assuming a common standard deviation of 25% and
all 45 patients having an evaluable primary endpoint. Nevertheless, to
meet regulatory requirements across the program, sample size was in-
creased to 471 (FH I) and 250 (FH II) to assess the safety of alirocumab
in a larger population (see Supplementary material online).
The ITT analysis included all randomized patients with an
LDL-C measurement available at baseline and at least one of the
ODYSSEY FH I and FH II 2997
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post-randomization time points between Weeks 4 and 24, regardless of
treatment adherence. Details on statistical analysis of efficacy endpoints
are given in Supplementary material online.
Results
Patients
A total of 735 patients were randomized in the two studies: 486 in
FH I (323 to alirocumab and 163 to placebo) and 249 in FH II (167 to
alirocumab and 82 to placebo; Figure 1). Baseline characteristics
were well balanced between groups in the individual studies, with
some differences noted between the studies (e.g. in percentage di-
agnosed by genotyping; Table 1). Prior CHD was reported in 46% of
patients in FH I and 36% in FH II, and CHD risk equivalents were pre-
sent in 16 and 8%, respectively (see Supplementary material online,
Table S1 for further details). Over 80% of patients were receiving
high-dose statin, and over half were also receiving ezetimibe
10 mg (Table 1). In FH I and FH II, respectively, 85.8 and 91.6% of
alirocumab-treated patients (87.7 and 90.1% of placebo) received
study treatment for ≥76 weeks.
Efficacy
In FH I, mean baseline LDL-C levels of 3.7 mmol/L (144.7 mg/dL)
were reduced to 1.8 mmol/L (71.3 mg/dL) at Week 24 in patients
randomized to alirocumab (placebo-corrected LDL-C reduction
of 57.9%; P, 0.0001). In FH II, mean baseline LDL-C levels of
3.5 mmol/L (134.6 mg/dL) were reduced to 1.8 mmol/L (67.7 mg/dL)
with alirocumab (placebo-corrected LDL-C reduction of 51.4%;
P, 0.0001; Table 2). LDL-C reductions were maintained through
Weeks 4–78 (Figure 2; data listed in mmol/L and mg/dL in Supple-
mentary material online, Table S2). After 78 weeks of treatment,
mean LDL-C levels were 2.2 mmol/L (84.0 mg/dL) in FH I (51.8%
reduction from baseline vs. placebo) and 1.8 mmol/L (69.7 mg/dL)
in FH II (52.1% reduction from baseline vs. placebo). The on-
treatment analysis of calculated LDL-C per cent change from base-
line to Week 24 showed very consistent results with the ITT analysis
(see Supplementary material online, Table S3). In order to assess
potential impact of missing data, a sensitivity analysis of the primary
endpoint using a pattern-mixture model was conducted and gave
results consistent with the primary analysis (see Supplementary
material online, Table S4).
An LDL-C level of ,1.8 mmol/L was achieved by 59.8% of pa-
tients (regardless of prior CV events) randomized to alirocumab
in FH I (vs. 0.8% placebo) and 68.2% of alirocumab-treated patients
in FH II (vs. 1.2% placebo) at Week 24 (Table 2). Achievement of
LDL-C levels of ,1.8 or ,2.6 mmol/L according to CV risk is
shown in Table 2. Significant reductions vs. placebo in apolipopro-
tein B, non-HDL-C, lipoprotein(a), and triglycerides as well as in-
creases in HDL-C and apolipoprotein A1 were also observed
following alirocumab treatment in both studies (Table 2; baseline
values in Supplementary material online, Table S5).
Per cent reductions in LDL-C at Week 12 (before potential dose
increase) are shown in Table 2. Among patients who received
Figure 1 Randomization and treatment. ITT, intention-to-treat. Completion of the study was defined as follows: last study-drug injection
received (Week 76) and end-of-treatment visit (Week 78) occurred within 21 days of last injection and at least 525 days post-randomization.
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double-blind treatment for at least 12 weeks, 176/311 (56.6%) in
FH I and 97/158 (61.4%) in FH II had LDL-C levels ,1.8 mmol/L at
Week 8 and were maintained on alirocumab 75 mg Q2W. LDL-C
levels were stable over time in these patients (see Supplementary
material online, Figure S1). For patients in FH I who received dose
increase to 150 mg Q2W, mean LDL-C levels were 2.7 mmol/L
(104.3 mg/dL) at Week 12 and 2.0 mmol/L (78.5 mg/dL) at Week
24. Corresponding values in FH II were 2.6 mmol/L (98.6 mg/dL)
at Week 12 and 1.9 mmol/L (71.8 mg/dL) at Week 24. The addition-
al percentage reduction in LDL-C following dose increase (i.e. com-
paring Week 12 to Week 24) was 15.1% in FH I and 16.9% in FH II.
Subgroup analyses of the primary efficacy endpoint showed con-
sistent reduction of calculated LDL-C across a range of demograph-
ic and baseline characteristics (Supplementary material online,
Figure S2). The percentage reduction in LDL-C (alirocumab vs.
placebo) was 60.1% in males and 50.6% in females (pooled data
from FH I and FH II), with a P-value for interaction of 0.0267. In
the individual studies, LDL-C reductions (vs. placebo) were 62.6%
for males and 51.9% for females in FH I and 53.5% for males and
49.2% for females in FH II.
Safety
The percentage of patients who experienced TEAEs, serious AEs,
and TEAEs leading to treatment discontinuation were comparable
between treatment groups in the individual studies (Table 3; further
details shown in Supplementary material online, Tables S6 and S7).
Positively adjudicated CV events were reported in eight (2.5%)
alirocumab-treated patients and three (1.8%) placebo patients in
FH I and in two (1.2%) alirocumab-treated patients and one
(1.2%) placebo patient in FH II. Six deaths (1.9%) were reported
in the alirocumab group of FH I (no deaths were reported in the
FH I placebo arm or in FH II). Events leading to death were metastatic
cancer in two patients (non-small cell lung cancer and pancreatic
cancer, diagnosed at 2.5 and 7.5 months following randomization,
respectively), acute MI in one patient, colonic pseudo-obstruction
following an abdominal surgery in one patient, and sudden cardiac
death in two patients (congestive cardiac failure and coronary artery
disease for the first death, and MI for the second death). Narratives
are given in the Supplementary material online.
A higher proportion of patients experienced injection site reac-
tions in the alirocumab groups vs. placebo in FH I (12.4 vs. 11.0%)
and FH II (11.4 vs. 7.4%). Most of the injection site reactions were
classified as mild in intensity. No injection site reaction led to study
drug discontinuation. None of the reported neurological or allergic
events (Table 3) were serious. Pruritus was reported in two (0.6%)
and three (1.8%) alirocumab-treated patients in FH I and II, respect-
ively, and one placebo-treated patient in each study (0.6 and 1.2%,
respectively). Few neurocognitive events were reported with aliro-
cumab [2 (0.6%) in FH I and none in FH II] or placebo [2 (1.2%) in
FH I, 1 (1.2%) in FH II; Table 3].
Among alirocumab-treated patients, 20 (6.2%) in FH I and 12
(7.2%) in FH II had calculated LDL-C levels of ,0.65 mmol/L
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Table 1 Baseline characteristics (randomized population)
FH I FH II
Alirocumab (n5 323) Placebo (n 5 163) Alirocumab (n 5 167) Placebo (n5 82)
Diagnosis of heterozygous familial hypercholesterolaemia, n (%)
Genotyping 129 (39.9) 62 (38.0) 117 (70.1) 66 (80.5)
Clinical criteriaa 193 (59.8) 101 (62.0) 50 (29.9) 16 (19.5)
Age, years, mean+ SD 52.1+12.9 51.7+12.3 53.2+12.9 53.2+12.5
Male, n (%) 180 (55.7) 94 (57.7) 86 (51.5) 45 (54.9)
Race, White, n (%) 300 (92.9) 144 (88.3) 164 (98.2) 80 (97.6)
Body mass index, kg/m2, mean+ SD 29.0+4.6 30.0+5.4 28.6+4.6 27.7+4.7
Coronary heart disease, n (%)b 147 (45.5) 78 (47.9) 58 (34.7) 31 (37.8)
Coronary heart disease risk equivalents, n (%)c 54 (16.7) 25 (15.3) 15 (9.0) 4 (4.9)
Current smoker, n (%) 39 (12.1) 30 (18.4) 36 (21.6) 13 (15.9)
Hypertension, n (%) 139 (43.0) 71 (43.6) 57 (34.1) 24 (29.3)
Type 2 diabetes, n (%)d 32 (9.9) 25 (15.3) 7 (4.2) 3 (3.7)
Statin use, n (%) 323 (100) 163 (100) 167 (100) 82 (100)
High-dose statin use, n (%)e 267 (82.7) 139 (85.3) 145 (86.8) 75 (91.5)
Ezetimibe use 181 (56.0) 97 (59.5) 112 (67.1) 53 (64.6)
FH I was conducted in North America, Europe, and South Africa; FH II was conducted in Europe. P-values comparing baseline data between treatment groups were calculated for
descriptive purposes, and no difference was significant at the 5% level.
aOne patient (randomized to the alirocumab arm in FH I) was characterized using clinical (World Health Organization) criteria as ‘probable’ HeFH rather than ‘certain’; however,
subsequent genotyping failed to identify a mutation in the LDLR or APOB genes; rare mutations cannot be excluded. The patient was considered as having HeFH by the investigator.
bAcute myocardial infarction, silent myocardial infarction, unstable angina, or coronary revascularization.
cIschaemic stroke, peripheral arterial disease, moderate chronic kidney disease (estimated glomerular filtration rate of ≥30 and ≤60 mL/min/1.73 m2), and diabetes with two or
more risk factors.
dBased on medical history.
eAtorvastatin 40–80 mg, rosuvastatin 20–40 mg, or simvastatin 80 mg daily.
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Table 2 Primary and selected secondary efficacy endpoints (intention-to-treat analysis)
FH I FH II
Alirocumab (n 5 322) Placebo (n 5 163) % Difference vs.
placebo
Alirocumab (n 5 166) Placebo (n 5 81) % Difference vs.
placebo
Calculated LDL-C, LS mean+ SE
Baseline, mmol/L [mg/dL] 3.7+0.1 [144.7+2.9] 3.7+0.1 [144.4+3.7] 3.5+0.1 [134.6+3.2] 3.5+0.1 [134.0+4.6]
Week 24, mmol/L [mg/dL] 1.8+0.1 [71.3+2.3] 4.0+0.1 [155.6+3.2] 1.8+0.1 [67.7+2.8] 3.5+0.1 [136.6+4.0]
% Change from baseline to Week 24
(primary endpoint)
248.8+1.6 9.1+2.2 257.9+2.7** 248.7+1.9 2.8+2.8 251.4+3.4**
95% confidence interval 263.3 to 252.6 258.1 to 244.8
Selected secondary efficacy endpoints
Patients (%) with or without prior CV events
achieving LDL-C ,1.8 mmol/L (,70 mg/dL)
or ,2.6 mmol/L (,100 mg/dL), respectively,
at Week 24
72.2** 2.4 81.4** 11.3
Patients (%) achieving LDL-C ,1.8 mmol/L at
Week 24 (regardless of prior CV events)
59.8** 0.8 68.2** 1.2
Calculated LDL-C % change from baseline to
Week 12, LS mean+ SE
243.5+1.4 5.7+2.0 249.2+2.4** 243.8+1.8 4.6+2.6 248.4+3.2**
% Change from baseline to Week 24 in secondary lipid variables, LS mean+ SE
Apolipoprotein B 241.1+1.2 4.7+1.6 245.8+2.0** 242.8+1.4 23.5+2.0 239.3+2.4**
Non-HDL-C 242.8+1.4 9.6+2.0 252.4+2.4** 242.6+1.8 3.1+2.5 245.7+3.1**
Lipoprotein(a) 225.2+1.4 27.5+2.0 217.7+2.5** 230.3+1.8 210.0+2.5 220.3+3.1**
Fasting triglycerides 29.6+1.6 6.3+2.2 216.0+2.7** 210.4+2.0 0.5+2.8 210.9+3.4*
HDL-C 8.8+0.9 0.8+1.2 8.0+1.5** 6.0+1.2 20.8+1.6 6.8+2.0*
Apolipoprotein A1 5.0+0.7 0.3+1.0 4.7+1.2* 2.8+0.9 21.6+1.3 4.4+1.6*
LS, least squares.
*P, 0.05; **P, 0.0001 vs. placebo.
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(,25 mg/dL) on at least two consecutive occasions. No specific
safety concerns were identified in these patients. Alanine transamin-
ase levels over three times the upper limit of normal were observed
in 1.6 and 3.6% alirocumab-treated patients in FH I and FH II,
respectively, compared with 1.2% placebo patients in both studies
(Table 3; further details in Supplementary material online, Table
S8). There were no differences between alirocumab and placebo
groups in terms of vital signs parameters except for a higher propor-
tion of patients with elevated systolic blood pressure in the FH II alir-
ocumab group (11.4%) vs. placebo (6.2%) (see Supplementary
material online, Table S9). There were no changes of note over the
course of the study in either HbA1c or estimated glomerular
filtration rate (Supplementary material online, Tables S10 and S11).
Anti-drug antibodies
Treatment-emergent ADA responses were observed in 17 (5.5%)
alirocumab and one (0.6%) placebo-treated patient in FH I and 14
(8.6%) alirocumab and one (1.3%) placebo-treated patient in FH II.
Six (1.8%) of these patients in FH I and three (1.8%) in FH II had such
a response on two or more consecutive sampling points. Median
time to onset of treatment-emergent ADA responses in
alirocumab-treated patients was 12 weeks in FH I and FH II. Three
patients [two (0.6%) in FH I and one (0.6%) in FH II] had positive
alirocumab-neutralizing antibody status at a single occasion (all at
Week 12). In one patient with a positive neutralizing status, a tran-
sient decline in efficacy was detected; however, by Week 16, LDL-C
levels were reduced by 66% from baseline. This reduction was main-
tained to end of study. LDL-C reduction was not affected in the
other two patients with positive neutralizing status. No specific
safety pattern was observed in ADA-positive patients.
Discussion
In patients with HeFH with inadequately controlled LDL-C levels
despite maximally tolerated statin with or without other LLT, self-
administered alirocumab reduced LDL-C levels from baseline by
57.9% (FH I) and 51.4% (FH II), vs. placebo, at Week 24. Alirocumab
was generally well tolerated over 78 weeks of treatment, with con-
sistent LDL-C reductions observed throughout the study. Although
mean LDL-C levels were .3.5 mmol/L at baseline, 56.6 and 61.4%
of patients in FH I and FH II, respectively, did not require dose
increase at Week 8 and were maintained on the dose regimen of
alirocumab 75 mg Q2W. Furthermore, the majority of alirocumab-
treated patients achieved LDL-C levels of ,1.8 mmol/L at Week
24 (59.8% in FH I and 68.2% in FH II).
LDL-C levels achieved in patients with HeFH have continued to
improve over the years as new lipid-lowering treatments become
available. In the first simvastatin trial, baseline LDL-C levels of
9.6 mmol/L (371 mg/dL) were reduced to 5.2 mmol/L (200 mg/dL)
with treatment.10 With the advent of more potent statins and the
addition of ezetimibe, LDL-C control has improved further.11 How-
ever, in recent studies, 80% of patients did not achieve an LDL-C
level of ,2.5 mmol/L.4,5 In FH I and FH II, baseline LDL-C levels of
3.5–3.7 mmol/L (135–145 mg/dL) were reduced to 1.8 mmol/L
(68–71 mg/dL), consistent with alirocumab Phase 1 and 2 trials in
patients with HeFH.7,12 Data from the FH I and II studies demon-
strate that PCSK9 inhibitors in addition to statins could for the first
time enable many patients with HeFH to achieve the specific LDL-C
goals suggested for individuals in the general population at risk for
CVD.9 However, given the chronic nature of this disease, further
studies of even longer duration are warranted.
In studies including mostly patients with non-familial hypercholes-
terolaemia (non-FH), alirocumab 75 mg Q2W (with possible dose
increase to 150 mg Q2W) reduced LDL-C by 48.2% (vs. 2.3%
with placebo)13 and 50.6% (vs. 20.7% with ezetimibe),14 consistent
with reductions observed in FH I and FH II. Furthermore, in a sub-
group analysis of the ODYSSEY LONG TERM study, alirocumab
dosed at 150 mg Q2W reduced LDL-C levels by a similar extent
in both patients with HeFH (256.3 vs. +7.0% with placebo) and
those with non-FH (262.1 vs. 20.5% with placebo).15
Subgroup analyses of FH I and FH II indicated larger percentage
reductions in LDL-C observed in males compared with females,
with the difference more prominent in FH I. However, the degree
of LDL-C lowering was still substantial for both sexes. Similar mild
heterogeneity in LDL-C reductions between sexes was reported in
previous alirocumab studies that included both patients with HeFH
and non-FH14,15 and also in studies of other PCSK9 inhibitors.16
Reasons for this heterogeneity are unclear at the present time.
As expected based on reductions in LDL-C, alirocumab also re-
duced levels of apolipoprotein B and non-HDL-C. Plasma levels of
Lp(a) were also significantly reduced. Lp(a) is an independent CV
risk factor, with levels reported to be higher in patients with FH
compared with controls.17 Statins have minimal if any effect on
Lp(a); however, reductions of 20.5–30.3% have been reported
with alirocumab treatment.13– 15,18
With regards to safety, a higher rate of injection site reactions was
reported with alirocumab compared with placebo in both studies,
although these were transient, non-serious events. Transient
Figure 2 Levels of calculated LDL-C over time (intention-to-
treat analysis). ALI, alirocumab; PBO, placebo.
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neutralizing antibodies were reported in three patients. Overall,
data in these patients do not suggest a correlation between neutral-
izing antibodies and LDL-C-lowering efficacy or safety, consistent
with a previous report.13 Six deaths were reported in the alirocu-
mab group in FH I; however, there was no pattern and no deaths
were felt to be drug related. However, neither FH I nor FH II was
powered for analysis of deaths or CV events, and current data
are insufficient to draw conclusions on the effect of alirocumab
on incidence of such events. In a 2341 patient 78 week study of
alirocumab 150 mg Q2W on background of maximally tolerated
statin with or without other LLTs (ODYSSEY LONG TERM), there
were fewer deaths in alirocumab-treated patients compared with
placebo. Furthermore, a post hoc analysis of ODYSSEY LONG
TERM indicated a lower rate of major adverse CV events with
alirocumab.15 The effect of alirocumab on CV events is being as-
sessed in the large 18 000 patient ODYSSEY OUTCOMES trial
(NCT01663402).
The FHI and II studies build on previous work from a smaller study7
and evaluated alirocumab over 18 months, the longest double-blind
treatment period to date with a PCSK9 inhibitor in patients with
HeFH. FH I and II demonstrated that alirocumab on top of maximally
tolerated statin produced sustained and clinically significant reductions
in LDL-C, with the majority of patients achieving LDL-C,1.8 mmol/L.
Alirocumab was well-tolerated in a large population of patients.
Supplementary material
Supplementary material is available at European Heart Journal online.
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Table 3 Treatment-emergent adverse events and laboratory values (safety population)
FH I FH II
Alirocumab (n 5 322) Placebo (n5 163) Alirocumab (n5 167) Placebo (n5 81)
TEAEs 263 (81.7) 129 (79.1) 125 (74.9) 66 (81.5)
Treatment-emergent SAEs 44 (13.7) 22 (13.5) 15 (9.0) 8 (9.9)
TEAEs leading to deatha 6 (1.9) 0 0 0
TEAEs leading to treatment discontinuation 11 (3.4) 10 (6.1) 6 (3.6) 1 (1.2)
TEAEs occurring in ≥5% patients (in any group)
Injection site reaction 40 (12.4) 18 (11.0) 19 (11.4) 6 (7.4)
Fisher’s exact test P-valueb 0.77 0.38
Nasopharyngitis 36 (11.2) 12 (7.4) 21 (12.6) 18 (22.2)
Upper respiratory tract infection 22 (6.8) 14 (8.6) 5 (3.0) 1 (1.2)
Arthralgia 20 (6.2) 9 (5.5) 8 (4.8) 7 (8.6)
Influenza 20 (6.2) 10 (6.1) 24 (14.4) 7 (8.6)
Back pain 18 (5.6) 7 (4.3) 12 (7.2) 6 (7.4)
Sinusitis 17 (5.3) 7 (4.3) 1 (0.6) 2 (2.5)
Headache 15 (4.7) 9 (5.5) 16 (9.6) 7 (8.6)
Diarrhoea 10 (3.1) 5 (3.1) 11 (6.6) 1 (1.2)
Bronchitis 10 (3.1) 9 (5.5) 4 (2.4) 1 (1.2)
Dizziness 7 (2.2) 6 (3.7) 8 (4.8) 5 (6.2)
Myalgia 6 (1.9) 11 (6.7) 10 (6.0) 5 (6.2)
Influenza like illness 6 (1.9) 1 (0.6) 9 (5.4) 5 (6.2)
Safety events of interest
Positively adjudicated CV events 8 (2.5) 3 (1.8) 2 (1.2) 1 (1.2)
General allergic TEAEsc 28 (8.7) 16 (9.8) 19 (11.4) 5 (6.2)
Neurological TEAEsc 12 (3.7) 7 (4.3) 7 (4.2) 2 (2.5)
Neurocognitive disordersc 2 (0.6) 2 (1.2) 0 1 (1.2)
Development/worsening of diabetesc 6 (1.9) 4 (2.5) 4 (2.4) 2 (2.5)
Ophthalmologic disordersc 3 (0.9) 4 (2.5) 3 (1.8) 1 (1.2)
Alanine aminotransferase .3 × ULN 5/322 (1.6) 2/163 (1.2) 6/166 (3.6) 1/81 (1.2)
Creatine kinase .3 × ULN 13/318 (4.1) 10/163 (6.1) 8/165 (4.8) 6/80 (7.5)
Values are n (%).
TEAE, treatment-emergent adverse event; SAE, serious adverse event; ULN, upper limit of normal.
aSix deaths occurred in the alirocumab group in FH I during study treatment, two due to metastatic cancer (non-small cell lung cancer and pancreatic carcinoma with secondary
Trousseau syndrome causing multiple embolic strokes), one due to acute MI, two classified as due to sudden cardiac death (congestive cardiac failure and coronary artery disease
for the first death, and MI for the second), and one due to colonic pseudo-obstruction following abdominal surgery.
bP-values for descriptive purpose only and not adjusted for multiplicity.
cSelection of preferred terms based on Custom Medical Dictionary for Regulatory Activities queries as shown in the Supplemental material online.
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